-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Author: Yuntian
Dimethyl Fumarate (DMF, trade name Tecfidera) is an oral relapsing multiple sclerosis drug developed by Biogen Idec
Figure 1.
First, the researchers found through cell inhibition experiments that dimethyl fumarate has a significant inhibitory effect on a variety of B-cell lymphoma cells, but has no inhibitory effect on other tumor cells such as K562 and U937.
Figure 2 Inhibitory effect of dimethyl fumarate on human diffuse B-cell lymphoma cells
Figure 3 The inhibitory effect of dimethyl fumarate on other tumor cells
Further research found that the main mechanism of action of dimethyl fumarate against diffuse B-cell lymphoma is to promote iron death through the GSH-Gpx4 pathway
Figure 4 GSH consumption experiment
In addition, the researchers found through experiments that dimethyl fumarate may exert an anti-tumor effect through the STAT3 pathway.
Figure 5.
Diffuse large B-cell lymphoma is a common clinical lymphoma
For the treatment of patients with diffuse large B-cell lymphoma, compared with the past, the current use of rituximab therapy can give patients greater benefits, but the effect is still limited
Note: The original text has been deleted
references:
1.
2.
3.
